Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
AlveoGene Logo
AlveoGene Growth Score
2
CB Rank
382826
Heat Score
8
AlveoGene is an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy.
Founded
obfuscation
PrivateSeed Oxford, Oxfordshire, United Kingdom1-10 alveogene.com/
Biotechnology
Health Care
Therapeutics
Overview

AlveoGene
Growth Score
2
Heat Score
8

Growth Score2
-1 pts
in past quarter
Heat Score 8
-6 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
See more interactive data and historical milestones on desktop for the best experience

About AlveoGene

CB Rank
382826
AlveoGene is an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy.
Founded
obfuscation
PrivateSeed Oxford, Oxfordshire, United Kingdom1-10 alveogene.com/
Biotechnology
Health Care
Therapeutics

Funding Rounds

Seed
OBF
in
obfuscation

Details

Legal Name AlveoGene Ltd.
Operating Status Active
Company Type For Profit
About the Company
AlveoGene is an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy.
Predictions & Insights

Growth Insight

See this Growth Insight
AlveoGene is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Growth Prediction

See this Growth Prediction
Top Contributing Factors
Growth Insight

Products & Services

AVG-002
An inhaled gene therapy designed to treat lethal neonatal Surfactant Protein B (SP-B) deficiency by delivering a functional SP-B gene to the lungs.
AVG-003
An inhaled gene therapy candidate targeting ABCA-3 deficiency, a rare pediatric genetic respiratory disorder, using the InGenuiTy® platform.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Seed Round - AlveoGene Logo
Seed Round - AlveoGene
3
obfuscation
— Seed
obfuscation
Seed Round - AlveoGene Logo
Seed Round - AlveoGene
3
obfuscation
— Seed
obfuscation
Seed Round - AlveoGene Logo
Seed Round - AlveoGene
3
obfuscation
— Seed
obfuscation
Seed Round - AlveoGene Logo
Seed Round - AlveoGene
3
obfuscation
— Seed
obfuscation
Seed Round - AlveoGene Logo
Seed Round - AlveoGene
3
obfuscation
— Seed

Funding Rounds

Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Seed Round - AlveoGene Logo
Seed Round - AlveoGene
3
obfuscation
— Seed
obfuscation
Seed Round - AlveoGene Logo
Seed Round - AlveoGene
3
obfuscation
— Seed
obfuscation
Seed Round - AlveoGene Logo
Seed Round - AlveoGene
3
obfuscation
— Seed
obfuscation
Seed Round - AlveoGene Logo
Seed Round - AlveoGene
3
obfuscation
— Seed
obfuscation
Seed Round - AlveoGene Logo
Seed Round - AlveoGene
3
obfuscation
— Seed

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 1-10
News

News and Press

News•Dec 3, 2024
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Dec 3, 2024
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Nov 15, 2024
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Nov 15, 2024
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

414
639.29%
 in past month

IT Spend

$140KThis year, AlveoGene is projected to spend $140K on IT, according to Aberdeen.

Active Website Tech Count

4AlveoGene is actively using 4 technologies for its website, according to BuiltWith. These include Common Crawl, CommonCrawl Top 50m, and  Euro.

Total IP

1AlveoGene has 1 registered trademark in the 'Chemical substances' class, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is AlveoGene's headquarters? AlveoGene is located in Oxford, Oxfordshire, United Kingdom.Who invested in AlveoGene? AlveoGene has 3 investors including Oxford Science Enterprises and  Old College Capital.When was the last funding round for AlveoGene? AlveoGene closed its last funding round on
obfuscation
from a Seed round.Who are AlveoGene's competitors? Alternatives and possible competitors to AlveoGene may include Avalyn Pharma, Verve Therapeutics, and  ReCode Therapeutics.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(ccb7a32 1)
|